Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
$1.83
-4.2%
$1.34
$0.95
$3.23
$11.29M-0.1321,911 shs118,857 shs
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
$0.38
-5.3%
$0.47
$0.35
$4.90
$11.98M1.21881,796 shs430,618 shs
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
$8.02
+0.3%
$8.61
$5.00
$100.80
$11.54M0.85258,923 shs58,834 shs
Jaguar Health, Inc. stock logo
JAGX
Jaguar Health
$4.62
+2.2%
$6.58
$4.02
$130.25
$3.11M0.9448,338 shs94,668 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
-4.19%-9.41%+71.03%+41.86%-39.63%
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
-5.33%-8.99%-23.88%-57.16%+37,679,900.00%
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
+0.25%-3.49%+8.53%-47.26%-81.77%
Jaguar Health, Inc. stock logo
JAGX
Jaguar Health
+2.21%+1.99%-61.47%-70.04%-95.76%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
1.3278 of 5 stars
0.02.00.03.43.01.70.6
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
1.4959 of 5 stars
3.50.00.00.00.01.70.6
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
2.1725 of 5 stars
3.52.00.00.01.63.30.0
Jaguar Health, Inc. stock logo
JAGX
Jaguar Health
2.7487 of 5 stars
3.55.00.00.04.10.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
0.00
N/AN/AN/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
3.00
Buy$10.002,553.93% Upside
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
3.00
Buy$35.00336.41% Upside
Jaguar Health, Inc. stock logo
JAGX
Jaguar Health
3.00
Buy$60.001,198.70% Upside

Current Analyst Ratings Breakdown

Latest JAGX, AYTU, HCWB, and CLDI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$120.00 ➝ $35.00
5/19/2025
Jaguar Health, Inc. stock logo
JAGX
Jaguar Health
First Berlin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
$81.66M0.14N/AN/A$4.64 per share0.39
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
$50K239.59N/AN/A($2.32) per share-0.16
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
$1.45M7.99N/AN/A$0.37 per share21.68
Jaguar Health, Inc. stock logo
JAGX
Jaguar Health
$11.55M0.27N/AN/A$4.02 per share1.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
-$15.84M-$0.72N/AN/A-7.62%-19.30%-4.80%N/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
-$24.99M-$23.25N/AN/A-1,067.82%-2,516.84%-132.95%N/A
Jaguar Health, Inc. stock logo
JAGX
Jaguar Health
-$41.30MN/A0.00N/AN/A-360.13%-326.62%-67.02%8/12/2025 (Estimated)

Latest JAGX, AYTU, HCWB, and CLDI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
N/A-$0.05N/A-$0.05N/AN/A
5/15/2025Q1 2025
Jaguar Health, Inc. stock logo
JAGX
Jaguar Health
-$18.50-$16.70+$1.80-$16.70$3.29 million$3.50 million
5/14/2025Q3 2025
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
-$0.17$0.20+$0.37$0.21$13.74 million$18.45 million
3/28/2025Q4 2024
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
N/A-$3.20N/A-$0.08N/A$0.40 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
N/AN/AN/AN/AN/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
N/AN/AN/AN/AN/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
N/AN/AN/AN/AN/A
Jaguar Health, Inc. stock logo
JAGX
Jaguar Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
0.32
0.98
0.81
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
N/A
0.19
0.19
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
N/A
0.07
0.07
Jaguar Health, Inc. stock logo
JAGX
Jaguar Health
1.65
1.84
1.36

Institutional Ownership

CompanyInstitutional Ownership
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
33.49%
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
12.53%
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
2.96%
Jaguar Health, Inc. stock logo
JAGX
Jaguar Health
12.04%

Insider Ownership

CompanyInsider Ownership
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
3.60%
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
24.28%
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
49.90%
Jaguar Health, Inc. stock logo
JAGX
Jaguar Health
0.38%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aytu BioPharma, Inc. stock logo
AYTU
Aytu BioPharma
1606.17 million6.00 millionNot Optionable
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
3831.79 million20.04 millionN/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
401.44 million22.32 millionNot Optionable
Jaguar Health, Inc. stock logo
JAGX
Jaguar Health
50674,00011.80 millionNo Data

Recent News About These Companies

Jaguar Health Reports First Quarter 2025 Financials
Jaguar Health files to sell 1.29M shares of common stock for holders

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aytu BioPharma stock logo

Aytu BioPharma NASDAQ:AYTU

$1.83 -0.08 (-4.19%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$1.81 -0.02 (-1.09%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Calidi Biotherapeutics stock logo

Calidi Biotherapeutics NYSE:CLDI

$0.38 -0.02 (-5.33%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$0.38 +0.01 (+1.65%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

HCW Biologics stock logo

HCW Biologics NASDAQ:HCWB

$8.02 +0.02 (+0.25%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$8.10 +0.08 (+1.00%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Jaguar Health stock logo

Jaguar Health NASDAQ:JAGX

$4.62 +0.10 (+2.21%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$4.64 +0.02 (+0.54%)
As of 04:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.